7 completed, 4 recruiting, 2 terminated, 2 unknown. 10 Phase 2, 4 Phase 4, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 4 | 4 | Completed 3, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Induction therapy: new trials by email Literature Review of Induction therapy trials Research Report on Induction therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy - Squamous Cell Carcinoma of the Anal Canal | Phase 2 | Not yet recruiting | Wang Xin | 34 | 2026-09-20 | 2026-09-08 |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel Cilta-cel, Cyclophosphamide, Induction therapy - Multiple Myeloma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 60 | 2025-10-03 | 2026-11-03 |
| Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial Induction Therapy, Maintenance Therapy - Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2025-09-04 | 2025-12-18 |
| Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC Induction therapy - Metastatic Breast Cancer | Phase 2 | Recruiting | Japan Breast Cancer Research Group | 106 | 2024-09-13 | 2025-01-30 |
| RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC RT 50 Gy, RT 54 GY, RT 60 GY - Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2022-06-14 | 2022-07-07 | |
| Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients Tacrolimus immediate-release formulation, Tacrolimus prolonged-release formulation, Induction therapy - Kidney Transplant | Phase 4 | Completed | Astellas Pharma China, Inc. | 284 | 2018-10-21 | 2024-10-31 |
| Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option induction therapy - Carcinoma, Non-Small-Cell Lung | Recruiting | Klinikum Esslingen | 50 | 2017-12-15 | 2022-08-16 | |
| Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer Chemotherapy, Radiation - Pancreatic Cancer | Phase 2 | Unknown | Campus Bio-Medico University | 50 | 2016-07-01 | 2022-06-01 |
| Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) Induction therapy, Corticosteroids, EVR+rCNI - End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD) | Phase 4 | Completed | Novartis Pharmaceuticals | 2037 | 2013-12-03 | 2019-01-30 |
| A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma PAD, VCD, ASCT - Multiple Myeloma | Phase 4 | Unknown | Peking University People's Hospital | 50 | 2013-05-01 | 2013-06-06 |
| Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer Radiation, Chemotherapy - Pancreatic Cancer | Phase 2 | Completed | Campus Bio-Medico University | 41 | 2013-03-01 | 2016-12-07 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Akt Inhibitor MK2206, Anastrozole, Goserelin Acetate - Estrogen Receptor Positive, HER2/Neu Negative | Phase 2 | Terminated | National Cancer Institute (NCI) | 16 | 2013-01-01 | 2018-05-08 |
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer Induction therapy - Breast Cancer | Phase 2 / Phase 3 | Completed | Women's Cancer Study Group GmbH | 4936 | 2012-05-01 | 2025-02-27 |
| Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis - Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ | Not applicable | Completed | Virginia Commonwealth University | 59 | 2011-04-01 | 2016-07-12 |
| Alloantibodies in Pediatric Heart Transplantation Induction Therapy, Tacrolimus, Mycophenolate Mofetil - Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 290 | 2010-01-01 | 2017-04-20 | |
| Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer Pentostatin, Sirolimus, Cyclophosphamide - Renal Cell Carcinoma, Graft-Versus-Host Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2008-03-01 | 2017-09-29 |
| Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC Ribavirin, Peg interferon alfa 2b, induction therapy - Hepatitis C | Phase 4 | Completed | Brooke Army Medical Center | 610 | 2002-02-01 | 2012-02-14 |
Breast Neoplasms (4) · Multiple Myeloma (2) · Pancreatic Neoplasms (2) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Graft vs Host Disease (1) · Hepatitis C (1) · Kidney Failure, Chronic (1) · Kidney Neoplasms (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · Squamous Cell Carcinoma of Head and Neck (1)
Campus Bio-Medico University (2) · National Cancer Institute (NCI) (2) · Astellas Pharma China, Inc. (1) · Brooke Army Medical Center (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Janssen Research & Development, LLC (1) · Japan Breast Cancer Research Group (1) · Klinikum Esslingen (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1) · Virginia Commonwealth University (1) · Wang Xin (1) · Women's Cancer Study Group GmbH (1)
United States (8) · China (4) · Germany (3) · Australia (2) · Canada (2) · Japan (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · Croatia (1)
Cynthia Ma (1) · Daniel H Fowler, M.D. (1) · Harry D. Bear, MD, PhD (1) · Jin Lu, PhD (1) · Lucio Trodella, MD (1) · Marshall Posner, MD (1) · Michele Fiore, MD (1) · Nadia Harbeck, Prof. Dr. (1) · Shuhua Yi, Dr (1) · Stephen A. Webber, MBChB, MRCP (1) · Stephen Harrison, MD (1) · Ulrike Nitz, Prof. Dr. (1)
PMID 26071480, PMID 29752413, PMID 31152476, PMID 31324444, PMID 32633157, PMID 34216395, PMID 34620664, PMID 40197799, PMID 42128502
2016 (1), 2025 (1), N01CM00071 (1), N01CM00099 (1), P30CA015083 (1), P30CA016059 (1), U01AI077867 (1)